Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q3 FY26 Earnings Presentation
18 slides from Dr. Reddy's Laboratories's earnings presentation, Jan 21, 2026
Slide 1: Regulation 30 intimation cover letter
Dr. Reddy's Laboratories Ltd. Dr. Raddy's ~;• •·· 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com January 21, 2026 National Stock Exchange of India Ltd. (S
Slide 2: Q3FY26 Results Update
Dr. Reddy’s Q3FY26 RESULTS UPDATE 21 JANUARY 2026 1 | September 2025 | Investor Presentation | As per consolidated financial statements under IFRS
Slide 3: Safe Harbor Statement
Safe Harbor Statement Dr. Reddy's ~;• •·· This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underly
Slide 4: Q3FY26 Financial Highlights
Q3FY26 Financial Highlights Dr.Reddy's ~;• •·· Double-digit growth in base business^; overall steady profitability, despite product specific headwinds r------------------------------------------------"" Revenues Impairment: in Middleburg due to DP One-time provision ₹ 8,727 Cr Impact of new Labour C
Slide 5: Q3FY26 Business Highlights
Q3FY26 Business Highlights Dr.Raddy's~;• •·· Continued progress on strategic priorities • Strategic collaboration with Immutep for commercialisation of a novel, immunotherapy oncology drug, Eftilagimod Alfa, in key Emerging Markets. Recombinant Hepatitis EVaccine (E. Coli) ,._,_,,Vo• Hevaxin • Launc
Slide 6: Q3FY26 Other Highlights
Q3FY26 Other Highlights Dr.Reddy's ~;• •·· ESG OTHER UPDATES • Announced Science-Based Net Zero Climate Targets - only Indian Pharma • USFDA conducted GMP inspection at CTO-SEZ API facility (Srikakulam), co to commit to such a target by FY2045. issued Form 483 with zero observations. • Leadership po
Slide 7: Q3FY26 Revenue Split
Q3FY26 Revenue Split Dr. Reddy's ~;• •·· Broad-based growth, aided by forex; moderated by product-specific headwinds in the US REVENUE BY SEGMENT GLOBAL GENERICS SPLIT North America Europe GLOBAL GENERICS ₹ 2,964 Cr ₹ 1,448 Cr 91% ₹ Overall 8,727 Cr • 12%YoY • 9%QoQ 34% 17% 20%YoY 5%QoQ 4.4% 0.9% Yo
Slide 8: Key Financial Metrics
Key Financial Metrics Dr.Reddy's ~;• •·· Sustaining growth & profitability, while investing for the future REVENUES GROSS MARGINS SG&A R&D EBITDA MARGINS (₹ Cr) (% of Revenues) (% of Revenues) (% of Revenues) (% of Revenues) n Q3FY26 8,727 Q3FY26 53.6% Q3FY26 30.8% Q3FY26 7.0% *Q3FY26 23.5% Q2FY26 8
Slide 9: Q3FY26 North America Performance
Q3FY26 North America Performance Dr.Raddy's~;• Moderated due to lower Lenalidomide sales and continued pricing pressure ,·------------------------------ ------ \ I I MARKET PERFORMANCE I I KEY UPDATES 34% ' I I I II 2.6% VS -0.3% I I I I I I II DRL Growth vs US Generics Market I I I • First-to-marke
Slide 10: Q3FY26 India Performance
Q3FY26 India Performance Dr.Reddy's ~;• Robust double-digit growth, continued outperformance of IPM r---------------------------------------------~ MARKET PERFORMANCE^ KEY UPDATES ' ''' 18% ''' '' '' '' 12.3% VS 11.9% '' '' 'Recombinant in Hepat<tis EVaccioe (E. Coli) ~-, ~ ''' ^DRL MQT Growth vs IP
Slide 11: Q3FY26 Emerging Markets Performance
Q3FY26 Emerging Markets Performance Dr. Reddy's ~;• •·· New product launches & favourable forex driving growth ,-- IE, ~ ....... \ ,-- -----------------------------------------, KEY UPDATES 22% COUNTRIES PRESENT IN • Collaboration with Immutep for commercialisation of novel, 48 immunotherapy oncolog
Slide 12: Q3FY26 Europe Performance
Q3FY26 Europe Performance Dr.Reddy's ~;• •·· Momentum in NRT business, new launches, aided by forex tailwinds ,..------------------------------------------------------, ,..-------------------------------------------------------, 17% KEY UPDATES COUNTRIES PRESENT IN • NRT integration progressing well
Slide 13: Q3FY26 PSAI Performance
Q3FY26 PSAI Performance Dr. Reddy's ~;• •·· Adverse Product mix impacting gross margins r------------------------------------------------------"'l r------------- ,----------------------~ KEY UPDATES 9% GROSS MARGIN • Non-binding strategic cooperation term sheet signed Q;_(J 17.3% VS 28.6% with Hybio
Slide 14: In Summary
In Summary Dr.Raddy's~;• A diversified business model with broad based levers STRENGTHEN CORE BUSINESSES ACROSS MARKETS ADVANCE KEY PIPELINE PRODUCTS (SEMAGLUTIDE, ABATACEPT) DRIVE EFFICIENCIES THROUGH BETTER OPERATIONAL LEVERAGE AUGMENT ORGANIC GROWTH WITH M&A AND IN-LICENSING STRENGTHEN CAPABILITI
Slide 15: At a glance
At a glance We accelerate access to affordable and innovative medicines because Good Health Can’t Wait. ~756mn patients reached globally $3.8bn Revenue 17% Revenue Growth 28% EBITDA Margin ~28% RoCE 26,000+ Employees globally 57 Nationalities (Employees) 83 Markets served 32 Plants (Manufacturing &
Slide 16: Consolidated Income Statement
Consolidated Income Statement Dr. Reddy's ~;• •·· Particulars (₹ Cr) Q3FY26 Q3FY25 YoY Gr % Q2FY26 QoQ Gr% 9MFY26 9MFY25 YoY Gr % Revenues 8,727 8,359 4.4 8,805 (0.9) 26,077 24,048 8.4 Cost of Revenues 4,046 3,453 17 3,991 1 11,720 9,731 20 :--·······················-··· ··························••
Slide 17: About Key Metrics and Non-GAAP Financial Measures
About Key Metrics and Non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non- GAAP financial measures are measures of our historical performance, financial position or cash flows that are
Slide 18: Good Health Can’t Wait.
Good Health Can’t Wait. 17 | September 2025 | Investor Presentation | As per consolidated financial statements under IFRS
Dr. Reddy's Laboratories — Q3 FY26 Earnings Presentation on 6ix